Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Avagenesis Corp. Announces Appointment of Chief Medical Officer


Print article Print article
2013-12-30 19:46:10 -

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.


Calgary, Alberta CANADA, December 30, 2013 /FSC/ - Avagenesis Corp. (VVA - TSX Venture), ("Avagenesis" or the "Company"), a biotechnology company engaged in the commercialization of medical technologies for use in the practice of regenerative medical aesthetics, is pleased to announce the appointment of Dr. Richard Cook, MD, MSc., FRCSC, as Chief Medical Officer.

"I am very excited to be joining Avagenesis as the Company advances from a research and development organization to a clinical stage company in the cosmetic surgery market and beyond," said Dr. Richard Cook.

Dr. Cook is a

Clinical Associate Professor of Surgery with the Division of Cardiovascular Surgery at the University of British Columbia and is an expert in complex mitral valve repair and minimally-invasive and robotic cardiac surgery. Dr. Cook holds an MD from the University of Alberta, and an MSc from the University of British Columbia (UBC). Following his cardiac surgical training at UBC, Dr. Cook completed subspecialty fellowship training at the Hopital Pitie-Salpetriere, in Paris, France, and at East Carolina University, in Greenville, North Carolina.

Dr. Cook is the only formally trained minimally-invasive and robotic cardiac surgeon in western Canada and is currently developing the first robotic cardiac surgery program in western Canada at Vancouver General Hospital. Dr. Cook is actively involved in clinical research at UBC as a co-investigator and collaborator in multiple clinical trials. Moreover, Dr. Cook is also a co-inventor and collaborator in National Institutes of Health sponsored trials of innovative technologies applicable to robotic cardiac surgery. He was formerly the co-director of the Resident Education program in cardiac surgery at UBC. He is also an examiner at the Royal College of Physicians and Surgeons of Canada, and is a member of the nucleus committee for the fellowship exam for Cardiac Surgery.

Dr. Cook is passionate about optimizing patient outcomes, and is excited by the opportunities allowed by recent advances in stem cell medicine. Being involved in cutting-edge technology such as robotically-assisted surgery and stem cells, as well as being involved in the training of future cardiac surgeons, he is at the forefront of new developments in medicine.

With Dr. Cook's appointment and the transition of Avagenesis to a clinical stage company, Avagenesis has accepted the resignation of Chris Chang, Ph.D., Chief Scientific Officer, effective immediately. The Company's Board of Directors wishes to thank Dr. Chang for his dedicated service to Avagenesis during its start-up phase of growth and development.

About Avagenesis Corp.

Avagenesis (formerly Therastem Life Sciences Inc.) was incorporated on December 10, 2010 under the Business Corporations Act (British Columbia) and continued into Alberta on February 11, 2011. On September 24, 2012, the Company changed its name from "Therastem Life Sciences Inc." to "Avagenesis Corp." Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of regenerative medical aesthetics. Avagenesis' development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells using patent-pending (in the United States and 18 other jurisdictions) and patented (in Australia and Singapore) bioprocessing and cell isolation technology.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis' current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development activities.. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Material factors and assumptions in this press release include the ability of Avagenesis to successfully transition to a clinical stage company and successfully execute its development activities.. Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.


Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.


For further information, please contact:

Avagenesis Corp.
Alan Tam, PFP, CA
Chief Financial Officer
Telephone: (604) 377-7575

To view the press release as a PDF file, please click on the following link:
www.usetdas.com/pr/avagenesis12302013.pdf


Source: Avagenesis Corp. (TSX-V - VVA) www.avagenesis.com
Maximum News Dissemination by FSCwire. www.fscwire.com


Author:
Fred Gautreau
e-mail
Web: www.fscwire.com
Phone: 14037173898

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser